New Anti-Infective Drug Aims to Fight Drug-Resistant Bacteria at the Source

NovaBay Pharmaceuticals, Inc. announces results from a Phase I clinical trial with NVC-422, a new compound with potent activity against numerous pathogens, including MRSA. NVC-422, whose trade name is AgaNase, is unique in that it is an anti-infective, but technically not an antibiotic.

Nasal colonization by Staphylococci is an important risk factor that predisposes carriers to nosocomial infections. NovaBay hopes that by greatly reducing this layer of colonizing bacteria, hospital patients will be less likely to experience serious MRSA infections.

NVC-422 rapidly destroys a range of pathogens that includes Gram-positive and Gram-negative bacteria, yeasts, and viruses. Because it kills pathogens on contact and not through typical antibiotic mechanisms, it is believed that bacteria and viruses are unlikely to develop resistance to NVC-422 treatment. This non-antibiotic strategy is critical for maintaining the efficacy of antibiotic therapies for life-threatening infections.

The recently completed Phase I trial demonstrated that topical application of NVC-422 to the lower nasal passages, or nostrils, is safe and well tolerated. Moreover, researchers could not detect any trace of NVC-422 in the blood.

The clinical study tested safety and tolerability following repeated applications of AgaNase at two drug concentrations, 0.1 percent and 0.3 percent, applied by spray or swab to the nostrils. Ninety-six subjects were enrolled and completed the study. Adverse events were local, mild and transitory and did not appear to increase with dosage.

Based on these results, NovaBay has begun a second Phase I trial to test the safety of NVC-422 at a higher dose. Results from this study should become available by early 2008. In parallel with the second Phase I study, NovaBay expects to begin a Phase IIa study by January 2008, in healthy volunteers who harbor S. aureus in their nasal passages.

NVC-422 could become a critical option in the ongoing battle against drug-resistant infections, including MRSA, said Dr. Ron Najafi, NovaBays president and CEO. We intend to move forward with additional safety and efficacy trials in volunteers and patients at risk of infection.

The target market for NVC-422 is hospital-associated infections, particularly those occurring in surgical wounds. Surgical site infection significantly lengthens hospital stays and may result in death. Hospital-associated MRSA infections cost the U.S. healthcare system tens of billions of dollars per year and are rapidly rising in frequency.

NovaBay has entered into a licensing and research collaboration agreement with an affiliate of Alcon, Inc. for the use of compounds similar to NVC-422 in eye, ear and sinus infections, and in contact lens solutions.

Source: Novabay Pharmaceuticals    

 

 

Hide comments

Comments

  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Publish